Psychedelics Companies PsyBio Therapeutics and Silo Wellness Start Trading on the OTCQB Venture Market

Psychedelics Companies PsyBio Therapeutics and Silo Wellness Start Trading on the OTCQB Venture Market

The OTCQB is a middle-tier market for entrepreneurial and development stage American and international companies.
Psychedelics Decriminalization Bill Clears Another Hurdle in California

Psychedelics Decriminalization Bill Clears Another Hurdle in California – But Not Without Controversy

The state's Assembly Public Health Committee wants to set legal limits on possession amount, and at least one advocacy organization thinks that's a problem.

BIG UPDATE On The LARGEST Psychedelic Therapy Clinical Trial: CMPS’ Psilocybin-Depression Study

HUGE UPDATE: Compass Pathways, (NASDAQ: CMPS), completes the LARGEST Phase 2b psilocybin clinical study to treat treatment resistant depression (TRD). This is the most important psychedelic therapy study that we know of because it is both the largest clinical trial testing psilocybin to date and it is also the most advanced in the clinical trial process. In this episode we will discuss: - The details of this trial and why it is so important; - The big update that we have for you; - When we can expect results; - Where the field goes from here in the near future. Timestamps: 0:00 - Intro 1:31 - What is Compass Pathways' Phase2b trial and why is it important? 6:57 - The major Update on CMPS' Clinical Trial 8:07 - Anticipated results date & what these results will mean for the psychedelic industry Enjoy the episode! Follow us on social media! 🙌 Instagram: @thepsychedelicinvestor Facebook: @thepsychedelicinvestor Want to collaborate? Send us an email at: thepsychedelicinvestor@gmail.com Music from: www.bensound.com Video editing: @themyaholy Check out our Benziga discounts https://benzinga.grsm.io/jameshallifax1834 https://benzinga.grsm.io/thepsychedelicinvestor DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change. #CompassPathways #CMPS #PsychedelicTherapy

Interview With Daniel Carcillo

In this episode of the Psychedelic Spotlight podcast we catch up with Daniel Carcillo, Founder and CEO of Wesana Health.
Awakn Life Science CEO Anthony Tennyson "Groundbreaking" MDMA discovery

Awakn Life Sciences CEO Details ‘Groundbreaking’ MDMA Discovery in Quest to Treat Addiction

, ,
Anthony Tennyson tells the Psychedelic Spotlight Podcast that his company has "discovered receptor sites that MDMA interacts with that we believe nobody else in the world knows about."
Wesana Health to Acquire Psytech

Wesana Health to Acquire Psychedelic Therapy and Software Company PsyTech

, ,
The deal creates Wesana Clinics, a chain of mental health facilities focused on delivering psychedelic-assisted psychiatric care, as well as data platform Wesana Solutions.
Megan Fox ayahuasca therapy

Ayahuasca Sent Megan Fox to ‘Hell for Eternity’ and It Was Better than Therapy

The actress is the latest celebrity to give ayahuasca a shot, following in the footsteps of Miley Cyrus and Chelsea Handler.
Psychedelics asthma treatment

Why Psychedelics Could Eventually Treat Asthma

,
Researchers continue to explore anti-inflammatory nature of psychedelics, which in small doses, may alleviate asthma symptoms.
Microdosing cancer patients LSD study

New Zealand Psychologist Assembles First Study Microdosing Cancer Patients with LSD

,
University of Auckland researcher hopes the psychedelic treatment will enhance the effect of psychotherapy, easing end-of-life distress in patients.

Numinus CEO Discussion: a LEADER in Psychedelic-Assisted Therapy? ( NUMI / LKYSF Stock)

Numinus Wellness (TSX.V: NUMI), (OTC: LKYSF), has been a constant topic of conversation on this channel. NUMI is a company working on psychedelic-assisted therapy: with MDMA for PTSD, in collaboration with MAPS; Ketamine Therapy for Depression; and Psilocybin therapy for addiction, That's why we decided to invite NUMI's CEO, Payton Nyquvest. I hope you all enjoy! Timestamps 1:00 - What is Numinus' mission? 2:37 - Numinus' partnership with MAPS to treat PTSD with MDMA 9:54 - Numinus treating addiction with Psilocybin 13:35 - Using ketamine to treat Depression 18:45 - Growing natural Psilocybin vs Synthetic versions? 21:45 -The 5-year plan 26:38 - What will revenues look like? Enjoy the episode! Check out our website: ThePsychedelicInvestor.com Follow us on social media! 🙌 Instagram: @thepsychedelicinvestor Facebook: @thepsychedelicinvestor Want to collaborate? Send us an email at: thepsychedelicinvestor@gmail.com Music from: www.bensound.com Video editing: @themyaholy Check out our Benziga discounts https://benzinga.grsm.io/jameshallifax1834 https://benzinga.grsm.io/thepsychedelicinvestor DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change. #Numinus #NUMIStock #numinus #numi #numistock